首页> 外文期刊>BMC Cancer >Synchronous bone metastasis in lung cancer: retrospective study of a single center of 15,716 patients from Tianjin, China
【24h】

Synchronous bone metastasis in lung cancer: retrospective study of a single center of 15,716 patients from Tianjin, China

机译:肺癌同步骨转移:中国天津天津15,716名患者的回顾性研究

获取原文
           

摘要

This study aimed to describe the incidence, clinical characteristics, and prognosis of lung cancer patients with synchronous bone metastasis (SBM) and to analyze the prognostic factors of the lung cancer patients with SBM. A total of 15,716 lung cancer patients who were diagnosed between 2009 to 2018 in the Tianjin Medical University Cancer Institute and Hospital were retrospectively reviewed. Among them, patients with SBM were checked. Both the demographic and clinical characteristics were included as follows: age, gender, marital status, history of smoking, alcohol consumption, family history of tumor, Karnofsky score, lymph node metastasis, histological type. Besides, laboratory data such as alkaline phosphatase, lactate dehydrogenase, carcinoembryonic antigen, squamous cell carcinoma antigen, cytokeratin-19 fragment, and neuron specific enolase were also included. The log-rank test and multivariate Cox regression analysis were employed to reveal the potential prognostic predictors. A further analysis using the Kaplan–Meier was employed to demonstrate the difference on the prognosis of LC patients between adenocarcinoma and non-adenocarcinoma. Among the included patients, 2738 patients (17.42%) were diagnosed with SBM. A total of 938 patients (34.3%) with SBM were successfully followed and the median survival was 11.53?months (95%CI: 10.57–12.49?months), and the 1-, 2-, and 5-year overall survival rate was 51, 17, and 8%, respectively. Multivariable Cox regression results showed history of smoking and high level of NSE were associated with the poor prognosis, while adenocarcinoma histological type was associated with better survival. The prevalence of SBM in lung cancer is relatively high with poor survival. The lung cancer patients with SBM showed diverse prognosis. Among all the pathological types, the division of adenocarcinoma suggested different prognosis of the lung cancer patients with SBM. The present study emphasized the importance of pathological diagnosis on prognostic determinants in lung cancer patients with SBM.
机译:本研究旨在描述同步骨转移(SBM)的肺癌患者的发病率,临床特征和预后,并分析SBM肺癌患者的预后因素。在2009年至2018年在天津医科大学癌症研究所和医院诊断出诊断的15,716名肺癌患者被回顾性审查。其中,检查患有SBM的患者。人口统计和临床特征都包括如下:年龄,性别,婚姻状况,吸烟,酒精消费,肿瘤家族史,Karnofsky评分,淋巴结转移,组织学类型。此外,还包括实验室数据,例如碱性磷酸酶,乳酸脱氢酶,癌胚抗原,鳞状细胞癌抗原,细胞角蛋白-19片段和神经元特异性烯醇酶。利用对数秩测试和多变量COX回归分析来揭示潜在的预测预测因子。采用Kaplan-Meier的进一步分析用于证明腺癌和非腺癌之间LC患者预后的差异。在包括的患者中,2738名患者(17.42%)被诊断为SBM。总共938名患者(34.3%)已成功遵循SBM,中位存活率为11.53?月份(95%CI:10.57-12.49?月份),以及1-,2-和5年的整体生存率51,17和8%。多变量的Cox回归结果表明,吸烟病史和高水平的NSE与预后差有关,而腺癌组织学型与更好的存活相关。 SBM在肺癌中的患病率相对较高,存活差。肺癌患者的SBM患者显示出不同的预后。在所有病理类型中,腺癌分裂表明SBM肺癌患者的不同预后。本研究强调了病理诊断对SBM肺癌患者预后决定因素的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号